Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: The Valsartan in acute myocardial infarction (VALIANT) trial

Circulation

Volumn 110, Issue 12, 2004, Pages 1572-1578

  Aguilar, David ^a,l   Solomon, Scott D ^b   Koøber, Lars ^c   Rouleau, Jean Lucien ^d   Skali, Hicham ^b   McMurray, John J V ^e   Francis, Gary S ^f   Henis, Marc ^g   O'Connor, Christopher M ^h   Diaz, Rafael ⁱ   Belenkov, Yuri N ^j   Varshavsky, Sergei ^k   Leimberger, Jeffrey D ^h   Velazquez, Eric J ^h   Califf, Robert M ^h   Pfeffer, Marc A ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f LERNER RESEARCH INSTITUTE   (United States)

^g Medical Pharmaceutical Consultants   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ Estudios Cardiologicos Latinoamerica   (Argentina)

^j INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^k ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^l UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

Diabetes mellitus; Heart failure; Myocardial infarction; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; VALSARTAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; COMORBIDITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; LIFE TABLES; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 20844456796     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000142047.28024.F2     Document Type: Article

References (33)

1. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100:1132-1133.
2. Berger AK, Breall JA, Gersh BJ, et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol. 2001;87:272-277.
3. Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care. 2001;24:1422-1427.
4. Vaccarino V, Parsons L, Every NR, et al. Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction. The National Registry of Myocardial Infarction 2 Participants. Am J Cardiol. 2000;85:1486-1489, A7.
5. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:171-179.
6. Pfeffer MA. McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
7. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J. 2000;140:727-750.
8. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. 1989;14:49-57.
9. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes, part II: potential mechanisms. Circulation. 2002; 105:1861-1870.
10. Mulvihill NT, Foley JB, Murphy RT, et al. Enhanced endothelial activation in diabetic patients with unstable angina and non-Q-wave myocardial infarction. Diabet Med. 2001;18:979-983.
11. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287: 2570-2581.
12. Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol. 1993;21:920-925.
13. Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA. 1991;266:528-532.
14. Chen J, Marciniak TA, Radford MJ, et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients: results from the National Cooperative Cardiovascular Project. J Am Coll Cardiol. 1999;34:1388-1394.
15. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-497.
16. Tenerz A, Lonnberg I, Berne C, et al. Myocardial infarction and prevalence of diabetes mellitus: Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes? Eur Heart J. 2001;22:1102-1110.
17. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-24.
18. Barzilay JI, Spiekerman CF, Kuller LH, et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care. 2001;24: 1233-1239.
19. Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24: 447-453.
20. Muhlestein JB, Anderson JL, Horne BD, et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 2003;146:351-358.
21. Taubert G, Winkelmann BR, Schleiffer T, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J. 2003;145:285-291.
22. Tenenbaum A, Motro M, Fisman EZ, et al. Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease. Am J Cardiol. 2000;86:1363-1366, A4-A5.
23. Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet. 1984;1:1264-1267.
24. Madsen JK, Haunsoe S, Helquist S, et al. Prevalence of hyperglycaemia and undiagnosed diabetes mellitus in patients with acute myocardial infarction. Acta Med Scand. 1986;220:329-332.
25. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144.
26. Henry RM, Kostense PJ, Spijkerman AM, et al. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation. 2003;107:2089-2095.
27. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773-778.
28. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
29. Wahab NN, Cowden EA, Pearce NJ, et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40:1748-1754.
30. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97:1695-1701.
31. Kersten JR, Toller WG, Tessmer JP, et al. Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism. Am J Physiol Heart Circ Physiol. 2001;281:H2097-H2104.
32. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41:1-7.
33. Shechter M, Merz CN, Paul-Labrador MJ, et al. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol. 2000;35:300-307.